Indian generic drug-maker Ranbaxy Laboratories pleaded guilty May 13, 2013 to seven federal criminal counts of selling adulterated drugs with intent to defraud, failing to report that its drugs didn’t meet specifications, and making intentionally false statements to the government.

As part of the proceedings in Baltimore federal court, a whistleblower lawsuit against Ranbaxy was also unsealed. The company will pay a total of $500 million in criminal and civil penalties to resolve the criminal case and the whistleblower suit.

Ranbaxy pleads guilty and pays $500 million fine May 2013 - Read this article with deep background information on Ranbaxy's problems.